due
emerg
new
variant
pathogen
microorgan
treatment
immun
infecti
diseas
becom
great
challeng
past
year
context
vaccin
develop
remark
effort
made
develop
new
vaccin
also
improv
efficaci
exist
vaccin
specif
diseas
date
vaccin
develop
protein
subunit
kill
pathogen
whilst
sever
vaccin
base
liveattenu
organ
carri
risk
regain
pathogen
certain
immunocompromis
condit
avoid
develop
riskfre
effect
vaccin
conjunct
adequ
deliveri
system
consid
imper
need
obtain
desir
humor
cellmedi
immun
infecti
diseas
last
sever
year
use
nanoparticlebas
vaccin
receiv
great
attent
improv
vaccin
efficaci
immun
strategi
target
deliveri
achiev
desir
immun
respons
cellular
level
improv
vaccin
efficaci
nanocarri
protect
antigen
prematur
proteolyt
degrad
facilit
antigen
uptak
process
antigen
present
cell
control
releas
safe
human
use
nanocarri
compos
lipid
protein
metal
polym
alreadi
use
attain
attribut
context
sever
physicochem
properti
nanoparticl
play
import
role
determin
vaccin
efficaci
review
articl
focus
applic
nanocarrierbas
vaccin
formul
strategi
use
function
nanoparticl
accomplish
effici
deliveri
vaccin
order
induc
desir
host
immun
infecti
diseas
twentyfirst
centuri
infecti
diseas
emerg
seriou
threat
health
million
peopl
across
globe
accord
world
health
organ
report
million
death
occur
due
lower
respiratori
infect
million
tuberculosi
alon
worldwid
past
decad
mani
new
infecti
diseas
emerg
old
diseas
reemerg
consid
longer
threat
human
collect
diseas
account
million
death
caus
enorm
impact
global
socioeconom
healthcar
sector
major
challeng
combat
diseas
mani
effect
drug
avail
one
plausibl
approach
could
base
applic
nanocarri
base
vaccin
howev
still
effect
vaccin
avail
preval
diseas
includ
immun
defici
syndrom
aid
tuberculosi
underlin
urgent
need
develop
desir
vaccin
diseas
import
aspect
optim
vaccin
includ
safeti
ii
stabil
iii
abil
elicit
durabl
adequ
immun
respons
minimum
number
dose
present
differ
gener
vaccin
attenu
kill
whole
organ
first
gener
subunit
second
gener
rna
dna
vaccin
third
gener
use
elicit
protect
immun
diseas
despit
sever
advantag
rna
dna
vaccin
minim
risk
infect
abil
elicit
immun
respons
specif
pathogen
cost
effect
number
challeng
associ
effici
deliveri
vaccin
molecul
target
site
requir
primeboost
vaccin
regimen
immunogen
agent
includ
prematur
degrad
molecul
inabl
translat
function
immunogen
similarli
protein
base
vaccin
use
success
sever
infecti
diseas
haemophilu
influenza
type
b
diphtheria
tetanu
acellular
pertusi
meningococcu
pneumococcu
howev
requir
adjuv
potenti
immunogen
also
encount
earli
degrad
exposur
hostil
milieu
introduc
recombin
proteinbas
vaccin
eg
recombin
hemagglutinin
vaccin
influenza
enhanc
immun
toward
infect
indic
applic
recombin
technolog
vaccin
product
overcom
hurdl
effici
vaccin
deliveri
system
requir
deliv
vaccin
molecul
target
site
evok
endur
immun
respons
also
minim
side
effect
requir
less
dose
moreov
increas
need
develop
new
gener
composit
vaccin
molecul
act
immunogen
well
adjuv
nanotechnolog
base
formul
offer
numer
advantag
develop
new
gener
vaccin
nanocarri
base
deliveri
system
protect
vaccin
prematur
degrad
improv
stabil
good
adjuv
properti
also
assist
target
deliveri
immunogen
antigen
present
cell
apc
sever
mechan
vaccin
deliv
specif
site
use
nanocarri
vaccin
antigen
encapsul
within
nanocarri
decor
surfac
figur
encapsul
within
nanoparticl
np
protect
antigen
prematur
proteas
degrad
elicit
sustain
releas
wherea
surfac
adsorpt
facilit
interact
cognat
surfac
receptor
toll
like
receptor
tlr
apc
nanocarri
base
deliveri
system
provid
suitabl
rout
administr
vaccin
molecul
enhanc
cellular
uptak
therebi
result
robust
innat
humor
cellular
well
mucos
immun
respons
compar
unconjug
antigen
review
mainli
focus
potenti
use
nano
deliveri
system
novel
vaccin
strategi
induct
innat
well
adapt
immun
respons
infecti
diseas
figur
schemat
represent
nanocarri
antigen
conjug
nanoparticl
surfac
incapsul
core
particl
decor
nanoparticl
surfac
target
molecul
eg
antibodi
fabfrag
peptid
etc
could
increas
deliveri
particl
antigen
present
cell
apc
induc
innat
adapt
immun
respons
immun
system
compos
collect
mobil
cell
traffic
throughout
bodi
well
resid
site
entri
ie
skin
respiratori
gastrointestin
genit
tract
search
invad
pathogen
cell
belong
two
major
type
innat
adapt
immun
system
innat
immun
cell
like
macrophag
neutrophil
rapidli
respond
pathogen
recogn
pathogen
surfac
moieti
phagocytosi
elimin
pathogen
activ
differ
antibacteri
effector
function
similarli
two
major
compon
adapt
immun
ie
bcell
import
gener
cell
mediat
humor
immun
respons
respect
cell
includ
helper
cell
secret
differ
cytokin
modul
function
b
cell
wherea
cell
recogn
destroy
viral
infect
cell
antibodi
produc
b
cell
neutral
invad
microb
clear
infect
cell
opson
pathogen
cellmedi
system
apc
particular
dendrit
cell
dc
macrophag
migrat
bodi
sampl
process
present
antigen
tcell
activ
cellular
immun
respons
cell
express
variou
surfac
receptor
recogn
cognat
ligand
danger
signal
trigger
activ
differ
signal
pathway
eventu
lead
activ
tcell
sampl
antigen
dc
migrat
peripher
tissu
drain
lymph
node
activ
naiv
tcell
wherea
macrophag
ingest
antigen
increas
lysosom
degrad
machineri
enhanc
antigen
present
activ
helper
cell
np
abl
stimul
differ
immun
cell
boost
host
immun
size
shape
surfac
chemistri
np
describ
detail
import
factor
determin
potenti
activ
immun
respons
gener
np
abl
stimul
immun
reaction
increas
synthesi
defens
gene
inflammatori
reaction
variou
type
np
like
gold
carbon
dendrim
polym
liposom
capabl
induc
cytokin
antibodi
respons
observ
case
administr
empti
pegyl
liposom
abl
elicit
igm
respons
invivo
model
besid
potenti
deliv
variou
immun
stimul
specif
site
well
deep
tissu
vaccin
molecul
alon
may
abl
reach
np
also
exploit
adjuv
augment
immunogen
vaccin
candid
nanoimmuno
stimul
nano
scale
nm
vaccin
particl
improv
vaccin
efficaci
vivo
better
bulk
molecul
known
nanoimmuno
stimul
use
specif
purpos
inorgan
np
iron
silica
polymer
np
chitosan
plga
pvponalk
liposom
cholesterol
lipid
viru
like
particl
vlp
differ
type
np
use
deliv
antigen
give
protect
differ
diseas
list
tabl
biocompat
inorgan
np
gold
carbon
silica
exploit
vaccin
deliveri
studi
np
synthes
variou
shape
size
surfac
modifi
form
viral
antigen
success
deliv
use
inorgan
np
carrier
caus
increas
antigen
stabil
protect
prematur
degrad
proteolyt
enzym
deliveri
viral
bacteri
antigen
use
gold
np
also
found
induc
quit
robust
host
immun
respons
influenza
immunodefici
viru
foot
mouth
tuberculosi
diseas
mice
encapsul
plasmid
dna
encod
mycobacteri
antigen
gold
np
exhibit
signific
reduct
mycobacterium
tuberculosi
caus
agent
human
tuberculosi
burden
infect
mice
studi
use
hollow
mesospor
silica
nanotub
spheric
form
carbon
np
adjuv
improv
immunogen
deliveri
protein
peptid
antigen
viral
infect
silica
base
np
contain
abund
silanol
group
util
introduc
specif
function
group
surfac
gain
access
vaccin
molecul
target
cell
major
advantag
inorgan
np
includ
low
product
cost
reproduc
safeti
applic
recent
year
polymer
np
receiv
great
attent
applic
deliveri
number
vaccin
primarili
due
eas
prepar
biodegrad
biocompat
reduc
cytotox
possibl
finetun
surfac
properti
need
moreov
rel
easi
control
rate
vaccin
releas
alter
composit
ratio
copolym
np
synthesi
process
commonli
use
polymer
np
vaccin
deliveri
poli
lacticcoglycol
acid
plga
poli
lactic
acid
pla
plga
np
alreadi
tri
deliveri
broad
rang
antigen
includ
hydrophob
antigen
hepatitisb
viru
antigen
bacillu
anthraci
tetanu
toxoid
ovalbumin
use
plga
conjug
antigen
exhibit
strong
immunostimulatori
properti
induc
cytokin
nitric
oxid
product
mycobacteria
infect
addit
synthet
polym
natur
biopolym
algin
pullan
inulin
chitosan
use
adjuv
inulin
known
activ
complement
cascad
confer
better
protect
hepat
b
influenza
virus
similarli
chitosan
np
demonstr
nanocarri
molecul
hbv
antigen
dna
vaccin
newcastl
diseas
vaccin
deliveri
plga
chitosan
np
conjug
vaccin
molecul
enhanc
immun
respons
mucos
site
recent
studi
also
show
deliveri
tuberculosi
lipid
use
biocompat
chitosan
np
abl
induc
signific
humor
well
cellular
immun
respons
compar
lipid
alon
mice
also
found
intraperiton
administr
conjug
show
better
activ
splenic
tcell
anoth
studi
de
titta
et
al
shown
intraderm
administr
cpg
conjug
polymer
np
increas
dendrit
cell
activ
sever
fold
exhibit
compar
vaccin
efficaci
time
lower
dose
also
caus
endur
cellular
immun
comparison
free
cpg
desir
properti
along
alreadi
known
reduc
toxic
biocompat
vitro
vivo
condit
make
polymer
np
plausibl
candid
preclin
pharmacokinet
therapeut
applic
addit
polymer
np
liposom
second
wide
explor
vaccin
drug
deliveri
vehicl
nanomedicin
field
synthesi
liposom
spontan
process
hydrat
lipid
enabl
lipid
bilay
format
around
aqueou
core
far
differ
type
liposom
includ
unilamellar
multilamellar
vesicl
compos
biodegrad
phospholipid
eg
phosphatidylserin
phosphatidylcholin
cholesterol
includ
vaccin
studi
liposom
deliv
vaccin
fusion
target
cell
membran
structur
flexibl
versatil
liposom
abl
encapsul
hydrophil
hydrophob
substanc
hydrophil
molecul
incorpor
aqueou
core
hydrophob
molecul
encas
within
phospholipid
bilay
earlier
report
shown
deliveri
antigen
protein
entrap
multilamellar
lipid
vesicl
elicit
strong
bcell
respons
similarli
antigen
peptid
conjug
phosphatidylserin
ps
liposom
readili
polypeptid
nanoparticl
rhodent
mamari
parasit
infect
surfac
protein
eimeria
falciformi
sporozoit
iscom
diarrhea
intern
apc
potenti
thelper
cell
mediat
immun
respons
deliveri
heat
shock
protein
encod
vaccin
dna
use
liposom
elicit
strong
protect
immun
fungal
infect
foreseen
applic
sever
liposom
base
vaccin
nanoformul
approv
clinic
trial
intracellular
pathogen
includ
virus
tuberculosi
one
studi
alreadi
demonstr
potenc
liposom
aerosol
carrier
gener
protect
immun
tuberculosi
infect
studi
tri
combin
dimethyl
dioctadecyl
ammonium
dda
lipid
base
liposom
variou
immunomodul
enhanc
immun
influenza
chlamydia
erythrocyticstag
malaria
tuberculosi
infect
context
dna
vaccin
lipiddna
complex
success
deliv
lung
monkey
sever
report
adequ
prove
applic
vlp
vaccin
carrier
also
abil
stimul
host
immun
respons
vlp
compos
selfassembl
viral
membran
form
monomer
complex
display
high
densiti
epitop
interestingli
vlp
also
engin
express
addit
protein
either
fusion
protein
particl
endogen
express
multipl
antigen
also
possibl
chemic
coupl
nonprotein
antigen
small
organ
molecul
onto
viral
surfac
produc
bioconjug
vlp
due
distinct
featur
vlp
provid
protect
viru
also
heterolog
antigen
specif
immun
respons
success
gener
deliveri
antigen
use
viru
capsid
protein
mammalian
cell
vlp
also
found
increas
immunogen
weak
antigen
exampl
salmonella
typhi
membran
antigen
influenza
protein
nef
gonadotropin
releas
hormon
gnrh
assembl
vlp
produc
strong
antigen
specif
humor
well
cellular
immun
respons
presum
use
vlp
base
nanoformul
could
enabl
antigen
achiev
conform
resembl
nativ
antigen
structur
thu
may
result
better
stimul
host
immun
respons
dendrim
three
dimension
monodispers
hyperbranch
nano
structur
made
mixtur
amin
amid
studi
explor
applic
dendrim
deliveri
differ
antigen
molecul
commonli
use
dendrim
vaccin
deliveri
polypropyleneimin
ppi
polyamido
amin
pamam
dendrim
singl
dose
dendrim
encapsul
multipl
antigen
found
produc
strong
antibodi
tcell
respons
ebola
viru
influenza
toxoplasma
gondii
gener
robust
immun
respons
found
due
effici
uptak
dendrim
host
cell
similarli
signific
increas
vaccin
efficaci
hiv
transactiv
transcript
tat
base
dna
vaccin
observ
due
enhanc
cellular
uptak
pmam
dendrim
henc
possibl
tailor
dendrim
attain
certain
biolog
physicochem
properti
also
feasibl
conjug
sever
ligand
singl
molecul
made
dendrim
promis
candid
develop
new
gener
vaccin
enhanc
immunogen
properti
cytokin
known
import
signal
molecul
secret
differ
cell
respons
extern
stimuli
cytokin
abl
activ
immun
cell
gener
protect
immun
sever
diseas
howev
cytokin
mostli
suscept
earli
degrad
subdu
particip
gener
host
immun
moreov
uncontrol
releas
cytokin
immun
respond
may
sometim
lead
harm
side
effect
overcom
limit
sever
studi
attempt
synthes
engin
nanocarri
achiev
effect
control
deliveri
cytokin
target
site
approach
found
reduc
toxic
improv
circul
time
antigen
specif
tcell
respons
comparison
free
cytokin
incorpor
granulocyt
macrophag
coloni
stimul
factor
gmcsf
interferon
alpha
nanocarri
exhibit
great
applic
cancer
therapi
nanocarri
conjug
cytokin
also
show
great
potenti
treatment
infecti
diseas
exampl
encapsul
microspher
induc
strong
protect
immun
tuberculosi
effect
due
product
high
antibodi
titer
result
sustain
control
releas
microspher
immun
mice
like
cytokin
sever
tolllik
receptor
tlr
agonist
also
explor
immun
activ
augment
immun
surveil
mechan
differ
immun
effector
cell
macrophag
bcell
dc
express
differ
type
tlr
known
interact
specif
pathogen
associ
molecular
pattern
pamp
specif
interact
eventu
initi
downstream
signal
cascad
ensur
elimin
gener
immun
pathogen
conjug
tlr
specif
agonist
nanocarri
help
target
molecul
specif
immun
cell
therefor
reduc
possibl
system
biodistribut
one
studi
shown
conjug
agonist
nano
polym
caus
effici
intern
apc
also
prolong
cell
respons
administr
np
load
vaccin
peptid
antigen
ligand
also
found
induc
strong
memori
effector
tcell
respons
anoth
studi
shown
conjug
agonist
polym
nanocarri
increas
activ
matur
naiv
dc
due
select
endocytosi
prolong
releas
immunogen
nanocarri
insid
dc
moreov
intraderm
inject
cpg
antigen
encapsul
polymer
np
rapidli
drain
lymph
node
activ
dc
studi
indic
np
use
tool
appropri
target
present
antigen
bcell
rich
lymphoid
organ
genet
molecul
dna
plasmid
rna
also
act
immunostimul
due
characterist
addit
less
risk
caus
diseas
particularli
immunocompromis
individu
genet
materi
consid
promis
candid
develop
next
gener
vaccin
administr
plasmid
vector
transloc
nucleu
initi
transcript
recombin
gene
use
host
cellular
machineri
recombin
dna
segment
encod
fusion
antigen
tuberculosi
show
great
potenti
new
tuberculosi
dna
vaccin
candid
similar
type
studi
conduct
past
vaccin
dna
rna
construct
express
mycobacterium
antigen
capabl
induc
humor
well
cellular
immun
respons
likewis
plasmid
harbor
gene
encod
viral
antigen
encapsul
algin
nanocarri
target
viral
infect
order
improv
deliveri
vaccin
characterist
differ
approach
practic
conjug
vaccin
molecul
differ
nanocarri
vaccin
molecul
surfac
conjug
encapsul
surfac
adsorb
nanocarri
antigen
adsorpt
nanocarri
simpli
base
presenc
charg
hydrophob
interact
np
candid
molecul
type
interact
usual
noncoval
may
lead
rapid
dissoci
antigen
nanocarri
depend
upon
extern
milieu
ph
ionic
strength
temperatur
antigen
hydrophob
hand
encapsul
chemic
conjug
antigen
nanocarri
stabl
due
strong
interact
chemic
bond
format
target
molecul
nanocarri
antigen
also
encapsul
nanocarri
simpl
mix
reaction
synthesi
case
antigen
releas
partial
complet
dissoci
nanocarri
process
alreadi
use
silica
gold
np
similarli
chitosan
dextran
sulfat
np
use
prepar
cation
anion
antigen
formul
viral
antigen
known
bind
posit
well
neg
charg
np
immobil
process
hydrogen
bond
immobil
process
depend
charg
ph
ratio
np
antigen
protein
partit
coeffici
solut
colloid
sever
antigen
success
deliv
target
site
chemic
conjug
adsorpt
encapsul
soft
nanocarri
like
vlp
liposom
immun
stimul
complex
iscom
iscom
class
adjuv
formul
consist
saponin
cholesterol
phospholipid
specif
ratio
antigen
formul
iscom
directli
surfac
modif
sinc
iscom
particl
neg
charg
direct
conjug
solubl
protein
limit
factor
nanocarri
augment
immunogen
molecul
exampl
influenza
antigen
conjug
chitosan
np
yersinia
pesti
coat
gold
np
aunp
produc
higher
level
antibodi
cytokin
respons
comparison
mice
administ
unconjug
antigen
found
due
stabil
increas
immunogen
vaccin
antigen
due
conjug
np
anoth
import
aspect
develop
nanoimmuno
formul
improv
antigen
deliveri
present
context
np
shape
size
surfac
charg
key
factor
affect
np
circul
biodistribut
bioavail
specif
cross
biolog
barrier
besid
factor
particl
geometri
surfac
volum
ratio
play
import
role
determin
immunogen
releas
degrad
kinet
import
differ
physicochem
paramet
size
shape
surfac
area
poros
hydrophob
hydrophil
crystallin
interact
np
target
cell
discuss
size
np
determin
mode
cellular
uptak
specif
plga
np
larg
size
show
reduc
intern
rate
comparison
smaller
np
nm
size
np
also
determin
cellular
specif
migrat
smaller
np
nm
readili
endocytos
resid
dc
wherea
larger
size
nm
np
effect
taken
migratori
dc
np
less
nm
size
drain
lymph
node
particl
nm
rang
suitabl
transport
apc
notabl
np
curvatur
also
affect
cellular
interact
phagocytosi
rate
np
nm
diamet
nm
height
show
cellular
uptak
compar
particl
nm
size
note
size
np
also
found
influenc
activ
signal
pathway
studi
demonstr
smaller
np
abl
alter
cell
signal
process
efficaci
larg
np
vaccin
load
np
also
target
specif
site
modifi
np
surfac
charg
deliveri
np
appropri
site
elicit
strong
immun
respons
antigen
np
surfac
charg
respons
interact
congnat
surfac
molecul
present
target
cell
exemplifi
observ
cation
polysteren
np
effici
intern
apc
comparison
neutral
surfac
charg
np
may
due
electrostat
interact
cation
np
anion
cell
membran
interestingli
pulmonari
instil
cation
anion
np
show
similar
endocytosi
rate
macrophag
drain
lymph
node
howev
cation
formul
show
express
chemokin
caus
recruit
matur
dc
comparison
anion
np
lung
similarli
neutral
silicasilan
shell
polym
np
less
effect
activ
innat
immun
cell
studi
clearli
indic
appropri
surfac
modif
np
may
help
gener
stronger
immunolog
respons
specif
infect
besid
size
surfac
charg
np
shape
also
critic
determin
cellular
interact
intracellular
traffick
rate
antigen
releas
insid
host
cell
spheric
gold
np
activ
intern
bone
marrow
deriv
dendrit
cell
comparison
rod
shape
particl
similar
dimens
spheric
np
abl
induc
strong
immun
respons
cube
rod
shape
np
anoth
studi
report
wormlik
particl
impair
phagocytosi
compar
spheric
np
distinct
ascrib
differ
contact
area
np
target
cell
membran
shape
np
also
determin
local
np
insid
host
cell
demonstr
fact
although
nano
rod
nano
sheet
intern
via
clathrin
mediat
endocytosi
nano
rod
particularli
deliv
nucleu
nanosheet
retain
cytoplasm
import
aspect
context
improv
antigen
process
present
tcell
well
establish
enhanc
antigen
process
present
achiev
candid
molecul
deliv
lysosom
compart
cell
hydrophob
np
play
signific
role
interact
solubl
protein
immun
cell
recognit
hydrophob
moieti
previou
studi
shown
hydrophob
polymer
np
strong
induc
cytokin
costimulatori
molecul
hydrophil
polymer
np
exposur
hydrophob
np
show
enhanc
activ
dc
induc
express
costimulatori
molecul
compar
hydrophil
one
similar
observ
report
innat
immun
cell
hydrophob
np
abl
activ
cell
upregul
express
proinflammatori
cytokin
encod
gene
also
facilit
opson
process
increas
adsorpt
immunoglobulin
cell
surfac
howev
studi
report
polyethylen
glycol
coat
pegyl
reduc
interact
np
immun
receptor
properti
consid
use
prevent
nonspecif
adsorpt
protein
np
therebi
prevent
uptak
apc
nonspecif
adsorpt
protein
uptak
phagocyt
cell
also
prevent
incorpor
alkyl
linker
peg
thiol
moieti
np
surfac
modif
np
alter
ligand
specif
interact
apc
conjug
molecul
surfac
np
modul
downstream
signal
cascad
also
reduc
np
intern
phagocyt
cell
function
np
agonist
increas
cytokin
product
express
immunoregulatori
gene
similarli
conjug
poli
methyl
vinyl
ethercomal
anhydrid
pvma
agonist
galactos
polym
np
shown
activ
complement
pathway
result
stabl
bind
complement
factor
lipoproteinlik
np
show
lp
scaveng
activ
therebi
result
inhibit
depend
inflammatori
respons
overal
studi
strongli
demonstr
tune
physicochem
properti
np
could
use
fundament
tool
target
vaccin
molecul
specif
site
induc
desir
immun
respons
emerg
studi
prove
nanocarri
use
mediat
develop
vaccin
variou
diseas
context
import
develop
np
formul
deliv
immunogen
apc
especi
dc
induc
effect
antigenspecif
tcell
respons
figur
sever
nanocarri
shown
specif
activ
dc
effectu
antitumor
antivir
immun
respons
zhu
et
al
propos
nanotio
fe
tio
particl
could
function
use
vector
promot
vaccin
deliveri
immun
cell
coincub
nanotio
fe
tio
dc
result
increas
product
also
upregul
express
mhc
class
ii
molecul
signal
pathway
way
immun
efficaci
variou
np
formul
erythrocyt
membraneenvelop
poli
llactidecoglycolid
plga
np
antigen
peptid
agonist
vlp
express
rsv
glycoprotein
chitosanco
sever
other
improv
np
also
control
cell
polar
differenti
branch
polyethyleniminesuperparamagnet
iron
oxid
np
bpeispion
promot
polar
dc
anoth
studi
sehgal
et
al
show
np
also
use
target
subset
particular
immun
cell
shown
simultan
target
dc
subset
ie
dcsign
np
synergist
stimul
activ
cellmedi
immun
compar
target
dc
subset
separ
preclin
macrophag
monocyt
highli
heterolog
cell
distribut
throughout
bodi
macrophag
process
present
antigen
elicit
adapt
immun
respons
due
intrins
phagocyt
natur
macrophag
easili
target
surfac
engin
np
cognat
ligand
agonist
macrophag
receptor
conjug
np
surfac
figur
discuss
sever
physicochem
paramet
np
size
surfac
charg
hydrophob
surfac
topographi
materi
composit
optim
facilit
interact
np
macrophag
receptor
rate
np
endocytosi
also
depend
upon
type
cell
surfac
receptor
ligand
conjug
np
surfac
exampl
np
target
via
mannos
fc
receptor
rapidli
intern
compar
scaveng
receptor
endocytosi
igg
antibodi
coat
np
show
uptak
rate
retent
time
insid
macrophag
without
affect
cell
viabil
also
posit
charg
np
interact
strongli
neg
charg
phospholipid
compon
cell
membran
hyperactiv
inflammatori
cell
also
restrict
control
releas
stimul
use
np
upon
activ
neutrophil
secret
varieti
cytokin
hydrolyt
enzym
respons
infect
prolong
neutrophil
activ
often
lead
acut
inflamm
tissu
damag
local
site
therefor
control
releas
molecul
necessari
prevent
hyperactiv
massiv
recruit
neutrophil
report
bovin
serum
albumin
bsa
np
abl
modul
function
neutrophil
follow
intern
intraven
inject
antiinflammatori
peptid
encapsul
polymer
np
reduc
neutrophil
recruit
subsequ
hyperinflamm
prevent
tissu
damag
use
np
deliv
vaccinedrug
control
fashion
consid
attract
approach
develop
therapeut
strategi
rang
acut
chronic
inflammatori
diseas
bcell
adapt
immun
system
express
repertoir
receptor
recogn
rang
antigen
activ
suppress
tcell
immun
determin
fate
diseas
number
np
base
therapeut
strategi
develop
regul
tcell
activ
viral
bacteri
fungal
infect
exampl
antivir
sirna
retrovir
drug
encapsul
lipid
np
dendrim
effect
deliv
tcell
block
hiv
replic
caus
signific
reduct
hiv
titer
compar
use
nonencapsul
retrovir
drug
tcell
activ
also
depend
type
size
np
use
deliveri
antigen
liposom
encapsul
antigen
better
present
cell
apc
deliveri
nm
ova
conjug
np
increas
mhc
class
ii
express
also
produc
higher
percentag
antigen
specif
cell
compar
nm
ova
conjug
particl
b
cell
abl
recogn
respond
microbi
surfac
antigen
bcell
receptor
activ
clonal
expans
antigen
specif
bcell
use
engin
np
exploit
develop
vaccin
differ
diseas
figur
encapsul
antigen
viru
like
particl
vlp
abl
induc
strong
durabl
humor
respons
compar
administr
expos
vaccin
molecul
potenc
immun
respons
also
depend
upon
mode
antigen
present
target
cell
surfac
conjug
immunogen
protein
peptid
abl
activ
b
cell
much
stronger
encapsul
antigen
singl
dose
plga
np
surfac
display
ovalbumin
ova
elicit
strong
antibodi
respons
vivo
compar
free
ova
np
also
use
activ
specif
immun
respons
studi
shown
peptid
conjug
carbon
nanotub
show
signific
antigen
specif
igg
respons
comparison
peptid
adjuv
alon
gener
antigen
captur
apc
extracellular
environ
target
endolysosom
compart
first
process
peptid
load
onto
class
ii
mhc
molecul
present
helper
cell
howev
cytosol
antigen
load
mhc
class
molecul
present
tcell
crucial
clearanc
viral
intracellular
infect
report
fraction
antigen
deliv
np
traffick
cytosol
vacuol
apc
present
mhc
class
molecul
np
mediat
cross
antigen
present
first
demonstr
antigen
conjug
iron
oxid
polym
np
addit
inorgan
polymer
np
also
use
antigen
deliveri
cytosol
context
lipid
np
shown
induc
cell
expans
effici
antigen
cross
present
viral
infect
invivo
model
similarli
invari
natur
killer
cell
inkt
special
subset
tcell
recogn
lipid
antigen
present
cell
plga
np
conjug
glycolipid
inkt
cell
stimul
increas
cytokin
releas
well
expans
antigen
specif
cell
cross
antigen
present
also
depend
upon
particleantigen
linkag
shown
disulfid
bond
np
antigen
caus
releas
antigen
endosom
compart
also
enhanc
cell
format
compar
nondegrad
linker
similarli
pulmonari
administr
np
effici
enhanc
cross
antigen
present
result
least
effector
cell
lung
adjuv
known
enhanc
prolong
immun
respons
antigen
deliveri
adjuv
antigen
use
np
found
use
prolong
exposur
lymphoid
organ
lymph
node
gener
robust
immun
respons
especi
import
small
adjuv
molecul
rapidli
clear
bloodstream
np
size
rang
nm
penetr
extracellular
matrix
travel
lymph
node
intern
resid
macrophag
activ
tcell
respons
biodistribut
np
also
depend
upon
rout
administr
size
observ
larger
particl
accumul
near
site
np
subsequ
endocytos
local
apc
wherea
smaller
np
drain
blood
capillari
peg
coat
liposom
nm
diamet
show
higher
accumul
lymph
node
subcutan
administr
compar
intraven
intraperiton
administr
nanoimmuno
formul
improv
antigen
stabil
target
deliveri
also
enhanc
immunogen
properti
solubl
antigen
effici
endocytos
apc
henc
poorli
effect
induc
protect
immun
immunogen
solubl
vaccin
antigen
improv
conjug
nanocarri
facilit
recognit
uptak
apc
strategi
alreadi
prove
effect
inducingincreas
immunogen
poorli
immunogen
antigen
polysaccharid
pneumococc
vaccin
last
year
applic
nanotechnolog
field
immun
engin
grow
rapidli
number
new
carrier
synthesi
strategi
furthermor
novel
nano
formul
also
contain
immunostimulatori
molecul
enhanc
adjuv
properti
nanoparticl
coencapsul
tlr
agonist
eg
cpg
poli
c
imiquimoid
dextran
chitosan
np
respect
enhanc
receptorbas
recognit
nanovaccin
subsequ
cell
activ
recent
studi
margaroni
et
al
show
vaccin
poli
llactidecoglycolid
plga
nanoparticl
leishmania
infantum
antigen
sliag
surfacemodifi
eightaminoacid
peptid
induc
signific
protect
parasit
infect
balbc
mice
accompani
activ
cell
increas
product
addit
np
tailor
noninvas
administr
prolong
deliveri
vaccin
antigen
specif
locat
thu
provid
possibl
formul
singl
dose
vaccin
sever
studi
clearli
demonstr
efficaci
noninvas
administ
vaccin
intranas
applic
influenza
nano
vaccin
chitosan
np
hemagglutinin
protein
influenza
viru
streptococcu
equi
protein
hepat
b
surfac
antigen
prccmvhb
plasmid
encod
multiepitop
protein
tuberculosi
antigen
use
provid
protect
immun
infect
consider
improv
progress
ongo
strategi
develop
nanoparticlebas
vaccin
futur
develop
nanovaccin
address
possibl
induc
immun
respons
also
antiinfect
therapeut
activ
np
thu
repres
feasibl
appli
multifunct
particl
treatment
diseas
rp
wrote
manuscript
supervis
process
ms
wrote
part
use
nanocarri
vaccin
deliveri
dendrit
cell
